Objective To observe the clinical application of omeprazole in chemotherapy patients with advanced non-small cell lung cancer(NSCLC). Methods Sixty-seven patients with advanced NSCLC were randomly divided into two groups. All patients were treated with chemotherapy with combination of two platiniferous drugs. The control group(n = 30) was given regular antiemetic drugs (ondansetrons, dexamethasone and metoclopramide, etc) on the first day of chemotherapy. The observation group(w= 37) was intravenously injected with 40 mg omeprazole (twice daily for 1-2 days and then once daily until 1-2 days after chemotherapy) after treatment with regular antiemetic drugs. Gastrointestinal reaction and the number of chemotherapy courses were compared between the two groups. Resnlts The total effective rate was 89. 2% for nausea and 75. 7% for vomiting in observation group,and 66. 7% for nausea and 63. 3% for vomiting in control group. The differences between the two groups were statistically significant (P<0. 05). In addition, the number of chemotherapy courses in observation group was more than that in control group (P<0. 05). Conclusion Omeprazole plays a role in preventing chemotherapy-induced gas-trointestinal reaction and may have antitumor activity against chemotherapy-resistant NSCLC.%目的 观察奥美拉唑在晚期非小细胞肺癌患者化疗中的临床应用价值.方法 将67例晚期非小细胞肺癌(Ⅳ期)患者按随机数字表法分为观察组(n=37)和对照组(n＝30),2组均给予含铂两药联合化疗方案进行治疗.对照组在化疗第1天给予常规止吐药恩丹西酮、地塞米松、胃复安等；观察组在化疗第1天给予常规止吐药后,另给予奥美拉唑40 mg静脉注射,开始每12h1次,1～2 d后改为每日1次,用至化疗结束后1～2 d.对2组患者出现的胃肠道反应和原始化疗方案疗程次数进行比较.结果 观察组恶心、呕吐总有效率分别为89.2％、75.7％,对照组恶心、呕吐总有效率分别为66.7％、63.3％,2组比较差异均有统计学意义(均P＜0.05).观察组原始化疗方案疗程次数多于对照组(P＜0.05).结论 奥美拉唑对化疗药物引起的胃肠道反应有一定的预防作用,对延缓化疗药物耐药可能有一定作用.
展开▼
